Longeveron (LGVN) EBT Margin Growth (3y) (2023 - 2026)
Longeveron (LGVN) EBT Margin Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 6,685.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2,054.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8,006.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,980.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,922.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 31,363.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -5,319.00 |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 48,208.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12,939.00 |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 260,861.00 |
| Sep 30, 2025 | -99,630.00 |
| Jun 30, 2025 | -109,831.00 |
| Mar 31, 2025 | -38,370.00 |
| Dec 31, 2024 | -2.24 Mn |
| Sep 30, 2024 | 924,244.00 |
| Jun 30, 2024 | 334,475.00 |
| Mar 31, 2024 | 438,777.00 |
| Sep 30, 2023 | -353,794.00 |
| Jun 30, 2023 | -232,994.00 |
| Mar 31, 2023 | -1.53 Mn |